Dune Medical Devices has received a €3m from the European Union (EU) to bring its RF spectroscopy technology to the biopsy market.
The grant was secured through the €80bn, seven-year EU Horizon 2020 program, which intends to secure Europe’s competitiveness globally.
Dune Medical said it is one of only 65 companies that will receive funding through the program.
Featuring radio frequency (RF) spectroscopy technology, the company's first commercial product MarginProbe has been helping surgeons ensure clean margins in lumpectomy procedures since 2013.
The company is now expanding its RF spectroscopy platform to develop the next generation product, which will enable surgeons to carry out biopsies.
It intends to develop a soft tissue biopsy system, which will be used in the treatment of breast tissue.
The new product will expand Dune’s surgical oncology portfolio to include a soft tissue biopsy breast tissue.
Dune Medical CEO and founder Dan Hashimshony said: “This three million euro grant will expedite bringing our soft tissue biopsy system to the market.
“It will provide radiologists and surgeons immediate graphic characterizations of tissue abnormalities along the tip of the biopsy needle, just before samples are taken.”
Dune Medical president Lori Chmura said: “Our biopsy device is another step along the path to a much broader spectrum of margin detection, which we believe will lead to applications in many other types of soft tissue analysis including other types of cancer surgeries.”